J

Jung S. Cho

West Virginia University

Publishes on Alzheimer's disease research and treatments, Nuclear Receptors and Signaling, Pharmacogenetics and Drug Metabolism. 28 papers and 569 citations.

28Publications
569Total Citations

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Alterations in behavior, amyloid p‐42, caspase‐3, and Cox‐2 in mutant PS2 transgenic mouse model of Alzheimer's disease
Dae Youn Hwang, Kab Ryong Chae, Tae Sun Kang et al.|The FASEB Journal|2002
Cited by 146

ABSTRACT Alzheimer's disease (AD) occurs when neurons in the memory and cognition regions of the brain are accompanied by an accumulation of the long amyloid p‐proteins of the 39 to 43 amino acids derived from the amyloid precursor protein (APP) by cleavage with p‐and γ‐secretase. An increased production of Ap‐42 by mutation of PS2 genes promotes caspase expression and is associated with the Cox‐2 found in the brain of AD patients. To address this question in vivo, we expressed the human mutant PS2 (hPS2m ) (N141I) as well as wild PS2 (hPS2w) as a control in transgenic (Tg) mice under control of the neuron‐specific enolase ( NSE ) promoter. Water maze tests were used to demonstrate the behavioral defect; dot blot, Western blot, and immunohistochemical analyses were performed on the brain with the hPS2, Ap‐42, caspase‐3, and Cox‐2 antibody. We concluded that 1) Tg mice showed a behavioral dysfunction in the water maze test, 2) levels of hPS2, Ap‐42, caspase‐3, and Cox‐2 expression were modulated in the brains of both Tg mice, 3) dense staining with antibody to hPS2, Ap‐42, caspase‐3, and Cox‐2 was visible in the brains of Tg mice compared with age‐matched control mice, and 4) distinguishable AD phenotypes between hPS2w‐and hPS2m‐Tg mice did not appear. These results suggest that an elevation of Ap‐42 by overexpression of hPS2 and mutation of hPS2m might induce the behavioral deficit and caspase‐3 and Cox‐2 induction, which could be useful in the therapeutic testing of compounds to have considerable clinical effects.—Hwang, D. Y., Chae, K. R., Kang, T. S., Hwang, J. H., Lim, C. H., Kang, H. K., Goo, J. S., Lee, M. R., Lim, H. J., Min, S. H., Cho, J. Y., Hong, J. T., Song, C. W., Paik, S. G., Cho, J. S., Kim, Y. K. Alterations in behavior, amyloid p‐42, caspase‐3, and Cox‐2 in mutant PS2 transgenic mouse model of Alzheimer's disease. FASEB J. 16, 805–813 (2002)

Use of<i>NSE/PS2m</i>-transgenic mice in the study of the protective effect of exercise on Alzheimer's disease
Jun Y. Cho, Dae Youn Hwang, Tae Sun Kang et al.|Journal of Sports Sciences|2003
Cited by 41Open Access

In its late stage, Alzheimer's disease results in progressive muscle weakness in the arms and legs. The aim of this study was to determine whether mice expressing the skeletal muscle-specific mutant PS2 gene (a model of Alzheimer's disease) are a useful experimental system to study the protective effect of exercise on A beta-42 reduction, improvement of behavioural function and changes in metabolic parameters. With this aim in mind, the transgenic mice were subjected to treadmill exercise for 3 months. The results showed that in transgenic mice, but not in normal mice, treadmill exercise resulted in a reduction of A beta-42 deposits and an improvement in behavioural function, thereby restoring normal concentrations of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglyceride. Thus, exercise may represent a practical therapeutic strategy for use with human patients with Alzheimer's disease.